Rigel Q3 net income $27.9M, raises 2025 revenue guidance to $285-290M

RIGEL PHARMACEUTICALS INC

2025-Q3 EPS reported $5.38 vs consensus $0.87 ▲ beat (+517.1%)

Q3 net income $27.9M ($1.46 diluted EPS) vs $12.4M ($0.70) in Q3 2024.
Total revenue $69.5M, record net product sales $64.1M (+65% YoY).
Raises 2025 total revenue guidance to ~$285-290M (prior $270-280M); product sales $225-230M.
TAVALISSE sales $44.7M (+70%), GAVRETO $11.1M (+56%), REZLIDHIA $8.3M (+50%).
R289 Ph1b dose expansion underway; Lilly terminates CNS collaboration (60-day effect).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.